Physician profile
Mark Laspina
NPI 1114181054
$5,297.74
in general payments reported to CMS, 2019-2025
31 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,676 · 2020: $1,382 · 2021: $280 · 2022: $54.30 · 2023: $23.94 · 2024: $156 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $921.14 | 2019-2024 | Xtandi |
| Neotract INC. | $522.55 | 2019-2020 | |
| Abbvie INC. | $390.25 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $386.70 | 2019-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $366.81 | 2019-2020 | |
| Janssen Biotech, INC. | $350.82 | 2019 | |
| Coloplast Corp | $347.50 | 2019-2021 | |
| Boston Scientific Corporation | $292.64 | 2019-2025 | Spaceoar Vue System - 10ml, General - Erectile Dysfunction, Ams 700 |
| Tolmar Pharmaceuticals, INC. | $234.81 | 2019-2020 | |
| Pfizer INC. | $162.28 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $147.06 | 2020-2025 | |
| Calyxo, INC. | $145.68 | 2025 | Cvac Aspiration System |
| Antares Pharma, INC. | $143.18 | 2019-2020 | |
| Therapeuticsmd, INC. | $115.52 | 2019-2020 | |
| Teleflex LLC | $112.42 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $107.23 | 2019-2020 | |
| Allergan, INC. | $79.14 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $73.46 | 2019 | |
| Acerus Pharmaceuticals Corporation | $69.96 | 2020 | |
| Travere Therapeutics, INC. | $48.04 | 2019 | |
| Amgen INC. | $40.82 | 2019-2020 | |
| Dentsply Ih INC. | $38.61 | 2020 | |
| Aytu Biopharma, INC. | $38.48 | 2019-2020 | |
| 180 Medical, INC. | $36.69 | 2019 | |
| Urogen Pharma, INC. | $26.66 | 2025 | |
| Tolmar, INC. | $23.94 | 2023 | |
| Medtronic USA, INC. | $17.91 | 2019 | |
| Ambu INC. | $17.21 | 2025 | |
| Merck Sharp & Dohme LLC | $14.24 | 2020 | |
| Procept Biorobotics Corporation | $13.60 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Laspina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.